Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
6.33
-0.17 (-2.62%)
At close: Jun 27, 2025, 4:00 PM
6.31
-0.02 (-0.32%)
After-hours: Jun 27, 2025, 7:55 PM EDT
Amylyx Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 7 professional analysts, the 12-month price target for Amylyx Pharmaceuticals stock ranges from a low of $4.00 to a high of $17. The average analyst price target of $11.14 forecasts a 75.99% increase in the stock price over the next year.
Price Target: $11.14 (+75.99%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Amylyx Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 1 | 1 | 3 |
Buy | 1 | 1 | 1 | 2 | 3 | 3 |
Hold | 4 | 4 | 4 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 7 | 7 | 7 | 4 | 5 | 7 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Guggenheim | Guggenheim | Strong Buy Initiates $17 | Strong Buy | Initiates | $17 | +168.56% | Jun 24, 2025 |
Citigroup | Citigroup | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +89.57% | Jun 17, 2025 |
Mizuho | Mizuho | Buy Maintains $7 → $8 | Buy | Maintains | $7 → $8 | +26.38% | May 14, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $12 → $16 | Strong Buy | Maintains | $12 → $16 | +152.76% | May 9, 2025 |
Leerink Partners | Leerink Partners | Hold → Buy Upgrades $4 → $10 | Hold → Buy | Upgrades | $4 → $10 | +57.98% | May 7, 2025 |
Financial Forecast
Revenue This Year
n/a
from 87.37M
Revenue Next Year
219.30K
EPS This Year
-1.83
from -4.43
EPS Next Year
-1.83
from -1.83
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | n/a | 677,250 | 29.7M | ||
Avg | n/a | 219,300 | 13.9M | ||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | 13,449.9% | ||
Avg | - | - | 6,251.1% | ||
Low | - | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -1.69 | -1.67 | -1.51 | ||
Avg | -1.83 | -1.83 | -1.79 | ||
Low | -1.86 | -1.89 | -1.98 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.